Marshall Wace
RARE icon

Marshall Wace’s Ultragenyx Pharmaceutical RARE Stock Holding History

Marshall Wace’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.3M Buy
157,526
+85,358
+118% +$1.92M ﹤0.01% 1521
2025
Q4 		$1.66M Sell
72,168
-73,926
-51% -$2.43M ﹤0.01% 1666
2025
Q3 		$4.39M Buy
146,094
+80,223
+122% +$2.41M ﹤0.01% 1239
2025
Q2 		$2.4M Sell
65,871
-268,207
-80% -$9.67M ﹤0.01% 1474
2025
Q1 		$12.1M Sell
334,078
-717,495
-68% -$29.8M 0.02% 702
2024
Q4 		$44.2M Buy
1,051,573
+229,561
+28% +$11.4M 0.05% 311
2024
Q3 		$45.7M Sell
822,012
-311,088
-27% -$15.8M 0.06% 303
2024
Q2 		$46.6M Buy
1,133,100
+164,110
+17% +$7.01M 0.06% 278
2024
Q1 		$45.2M Sell
968,990
-520,496
-35% -$24.6M 0.07% 280
2023
Q4 		$71.2M Buy
1,489,486
+548,723
+58% +$21.3M 0.12% 168
2023
Q3 		$33.5M Buy
940,763
+14,126
+2% +$560K 0.07% 295
2023
Q2 		$42.7M Buy
926,637
+21,112
+2% +$979K 0.08% 260
2023
Q1 		$36.3M Buy
905,525
+570,100
+170% +$24.5M 0.08% 288
2022
Q4 		$15.5M Buy
335,425
+254,711
+316% +$10M 0.04% 574
2022
Q3 		$3.34M Sell
80,714
-270,936
-77% -$13.9M 0.01% 1676
2022
Q2 		$21M Sell
351,650
-33,803
-9% -$2.08M 0.04% 446
2022
Q1 		$28M Buy
385,453
+151,223
+65% +$10.5M 0.05% 384
2021
Q4 		$19.7M Buy
234,230
+204,288
+682% +$16.6M 0.04% 495
2021
Q3 		$2.7M Sell
29,942
-5,587
-16% -$505K 0.01% 1335
2021
Q2 		$3.39M Buy
+35,529
New +$3.7M 0.02% 1071
2021
Q1 		– Sell
-26,014
Closed -$3.6M – 2793
2020
Q4 		$3.6M Buy
+26,014
New +$3.09M 0.02% 697
2016
Q1 		– Sell
-29,656
Closed -$3.33M – 1167
2015
Q4 		$3.33M Sell
29,656
-44,337
-60% -$4.43M 0.03% 469
2015
Q3 		$7.13M Buy
73,993
+14,044
+23% +$1.61M 0.09% 231
2015
Q2 		$6.14M Sell
59,949
-62,664
-51% -$4.87M 0.08% 265
2015
Q1 		$7.61M Buy
+122,613
New +$6.81M 0.1% 242

Other funds holding RARE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Marshall Wace's RARE Position: Q1 2026 in Review

Marshall Wace increased its Ultragenyx Pharmaceutical (RARE) stake by 118% in Q1 2026, buying an estimated $1.92M and bringing the position to 157,526 shares worth $3.3M. The position accounts for ﹤0.01% of the portfolio, ranked #1521.

Marshall Wace first reported a position in RARE in Q1 2015 and has held it in 25 quarters since. The position peaked at $71.2M in Q4 2023. 296 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

  • Marshall Wace held 157,526 shares of Ultragenyx Pharmaceutical worth $3.3M as of Q1 2026.
  • Marshall Wace bought 85,358 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $1.92M.
  • Ultragenyx Pharmaceutical made up ﹤0.01% of Marshall Wace's portfolio in Q1 2026, its #1521 holding.
  • Marshall Wace first reported a position in Ultragenyx Pharmaceutical in Q1 2015 and has held it in 25 quarters since.
  • Marshall Wace's Ultragenyx Pharmaceutical position peaked at $71.2M in Q4 2023.
  • 296 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.